MEI Pharma Inc  

(Public, NASDAQ:MEIP)   Watch this stock  
Find more results for MEIP
7.09
+0.32 (4.73%)
Aug 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.57 - 7.25
52 week 5.51 - 13.98
Open 6.75
Vol / Avg. 0.00/69,395.00
Mkt cap 146.28M
P/E     -
Div/yield     -
EPS -1.14
Shares 21.61M
Beta 1.33
Inst. own 90%
Aug 14, 2014
MEI Pharma Inc at Canaccord Genuity Growth Conference
Aug 13, 2014
MEI Pharma Inc at Wedbush Securities Life Sciences Conference
Jun 17, 2014
MEI Pharma Inc at Wells Fargo Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -50.56% -52.12%
Return on average equity -53.26% -56.68%
Employees 13 -
CDP Score - -

Address

Suite 101, 11975 El Camino Real
SAN DIEGO, CA 92130
United States - Map
+1-858-7926300 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

MEI Pharma, Inc., formerly Marshall Edwards, Inc., is a development-stage oncology company. The Company is engaged in the development of drugs for the treatment of cancer. The Company focuses on the clinical development of therapeutics targeting cancer metabolism. The Company is a wholly owned subsidiary of Novogen Limited (Novogen). As of September 26, 2011, Novogen owned approximately 51.5% interests in the Company. The Company's has two geographic segments: the United States and Australia. The Company has two clinical product development programs, which include NADH Oxidase Inhibitors and Mitochondrial Inhibitors. NADH Oxidase Inhibitors includes Phenoxodiol and ME-143. Mitochondrial Inhibitors includes NV-128 and ME-344. Marshall Edwards Pty Ltd. is a wholly owned subsidiary of the Company. In February 2013, Novogen Limited completed its exchanged offer through which it was to split off its 63.5% interest in the Company.

Officers and directors

Daniel P. Gold Ph.D. President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Thomas M. Zech Chief Financial Officer
Age: 62
Bio & Compensation  - Reuters
Robert D. Mass M.D. Chief Medical Officer
Bio & Compensation  - Reuters
Christine Anna White M.D. Lead Independent Director
Age: 62
Bio & Compensation  - Reuters
Charles V. Baltic III Independent Director
Age: 52
Bio & Compensation  - Reuters
Leah Rush Cann Independent Director
Age: 53
Bio & Compensation  - Reuters
Nicholas Glover Ph.D. Independent Director
Age: 44
Bio & Compensation  - Reuters
Thomas C. Reynolds M.D., Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters